Physician profile
Robert Eric Hart
NPI 1326044504
$5,146.05
in general payments reported to CMS, 2019-2025
44 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $802 · 2021: $908 · 2022: $969 · 2023: $892 · 2024: $713 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $849.36 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $779.22 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $599.04 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Janssen Pharmaceuticals, INC | $399.63 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $205.98 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $189.68 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $188.95 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $162.79 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.28 | 2021-2024 | |
| Astellas Pharma US INC | $151.29 | 2021-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $134.16 | 2022-2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $131.41 | 2022-2024 | Quviviq |
| Globus Medical, INC. | $114.67 | 2019 | |
| Phathom Pharmaceuticals, INC. | $107.78 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $103.45 | 2023 | Gemtesa |
Show all 39 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.